Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

RNAVery BullishCorporate Developmentsnews

High materiality9/10

Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday

Oct 27, 2025, 12:33 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The acquisition significantly enhances Novartis's RNA capabilities, appealing to investors. Historically, similar deals have increased stock valuations substantially, such as Gilead's acquisition of Kite Pharma.

AI summary

What happened, with direct paths to the underlying reporting

Novartis is acquiring Avidity Biosciences for $12 billion in cash. The deal represents a 46.5% premium over Avidity's last closing price. This acquisition expands Novartis's portfolio in RNA-based therapies. Avidity's stock jumped over 40% due to the acquisition announcement. Dyne Therapeutics also rose significantly, benefiting from this acquisition.

Novartis is acquiring Avidity Biosciences for $12 billion in cash.
The deal represents a 46.5% premium over Avidity's last closing price.
This acquisition expands Novartis's portfolio in RNA-based therapies.
Avidity's stock jumped over 40% due to the acquisition announcement.
Dyne Therapeutics also rose significantly, benefiting from this acquisition.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.